A Multicenter Randomized Double Blind Placebo Controlled Parallel Group Pilot Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects with Relapsing-remitting Multiple Sclerosis

Study Overview

The purpose of this study is to examine the safety, tolerability and response rate of Acthar in subjects with RRMS who have not responded to high dose intravenous methylprednisolone (IVMP), oral prednisone, or oral methylprednisolone.

Study Description

The purpose of this study is to examine the safety, tolerability and response rate of Acthar in subjects with Relapsing-remitting multiple sclerosis (RRMS) who have not responded to high dose intravenous methylprednisolone, oral prednisone, or oral methylprednisolone.

Additional Information

Participants will be compensated for their participation.


  • IRB Number: 1706802372
  • Research Study Identifier: TX8265
  • Principal Investigator: Jaison Grimes, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176